Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.56 |
| ▸ | PREP | P48147 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357066 | 1.00 | DPP4 (0.56) | DPP4DPP8DPP9PREPCTSK | |
| SCHEMBL240005 | 1.00 | DPP4 (0.56) | DPP4DPP8DPP9PREPCTSK | |
| SCHEMBL19055875 | 0.95 | DPP4 (0.51) | DPP4DPP8DPP9PREPCTSK | |
| SCHEMBL3966030 | 0.95 | DPP4 (0.51) | DPP4DPP8DPP9PREPCTSK | |
| SCHEMBL82202 | 0.95 | DPP4 (0.51) | DPP4DPP8DPP9PREPCTSK | |
| SCHEMBL16067363 | 0.90 | CTSK (0.49) | DPP4DPP8DPP9CTSKHSD17B10 | |
| SCHEMBL6166916 | 0.90 | CTSK (0.49) | DPP4DPP8DPP9CTSKHSD17B10 | |
| SCHEMBL5374793 | 0.86 | HSD17B10 (0.49) | DPP4DPP8DPP9PREPHSD17B10 | |
| SCHEMBL6213019 | 0.86 | HSD17B10 (0.52) | DPP4DPP8DPP9CTSKHSD17B10 | |
| SCHEMBL5171011 | 0.85 | HSD17B10 (0.49) | CTSKHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | H LEE MOFFITT CANCER CT & RES (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2024035771-A2 | ULK3 INHIBITORS AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| CN-112812074-B | Tetrazine compound and preparation method and application thereof | 四川大学华西医院 | 2022-06-14 | — | — | CN | disclosed |
| CN-112812074-A | Tetrazine compound and preparation method and application thereof | 四川大学华西医院 | 2021-05-18 | — | — | CN | disclosed |
| US-20120214858-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-23 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | DPP4 801/4885DPP8 1382/4885DPP9 1346/4885 |
| US-20070259926-A1 | mGluR5 modulators III | GRM5, GRM3, GRIK5 | DPP4 760/4885DPP8 1398/4885DPP9 1231/4885 |
| US-20120214858-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | SPHK2, SPHK1, S1PR2 | DPP4 2544/4885DPP8 1722/4885DPP9 2114/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | DPP4 1580/4885DPP8 2865/4885DPP9 2121/4885 |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | ULK3, ULK1, ULK2 | DPP4 4238/4885DPP8 3098/4885DPP9 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.